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Abstract
Purpose There is increasing concern with regard to fatal intoxications with prescription opioids and tramadol poisonings. This
study aimed to characterise prescribing patterns for tramadol in primary care in France and Germany and identify long-term
treatment and potential risk factors for such treatment.
Methods Adult patients-prescribed tramadol between January 2006 and June 2016 in GP practices in IMS® Disease Analyzer
databases in France and Germany were identified. Six-monthly prevalence and mean doses and durations were calculated by
gender, age group and type of tramadol product. The proportion of incident use that resulted in treatment ≥ 366 days was
calculated. The odds for long-term treatment was analysed in relation to gender, age group, type of tramadol product, start dose,
indication and a diagnosis of abuse or misuse.
Results Overall prescribing of tramadol decreased in Germany and increased, then plateaued in France. Prescribing was higher in
females. Predominantly prescribed products were tramadol in combination with paracetamol (COMB) in France and slow release
formulations of tramadol (SR-TRAM) in Germany. SR-TRAM had the highest mean doses and durations, followed by imme-
diate release formulations of tramadol (IR-TRAM) and COMB. Around 1.5% of incident tramadol use in France and 8.2% in
Germany resulted in long-term treatment. Long-term treatment was associated with increasing age, SR-TRAM and a diagnosis of
abuse or misuse.
Conclusions The risk of long-term treatment appeared to increase with increasing age. Potential risk factors for long-term
treatment included initiating treatment with SR-TRAM and a diagnosis of abuse or misuse.
Keywords Opioids . Pain . Drug utilisation . Clinical pharmacology . Chronic pain
Introduction
Tramadol is a weak opioid analgesic indicated for the treat-
ment of moderate to severe pain. The analgesic effect is
mediated by binding to opioid receptors and inhibition of se-
rotonin and norepinephrine reuptake [1]. The active metabo-
lite o-desmethyltramadol [2], which is formed by the poly-
morphic enzyme CYP2D6 [3, 4], and not tramadol itself, is
responsible for its opioid effects. Tramadol is regarded to have
a low potential for abuse and misuse, and is therefore not
scheduled in the German Narcotic Drugs Act [5] nor in the
French decree on narcotics [6] in contrast to some other coun-
tries such as the UK.
However, drug abuse has been reported for tramadol [7, 8],
and dependence may occur when tramadol is used for periods
longer than weeks tomonths, particularly in case of high doses
[2]. Tramadol has also been associated with fatal intoxications
when used in combination with other pharmaceutical sub-
stances, illicit drugs or ethanol [2, 9, 10]. Fatal intoxications
with prescription opioids have prompted an increasing con-
cern internationally [11–16]. In this context, the European
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Monitoring Centre for Drugs and Drug Addiction
(EMCDDA) launched a new call for data on tramadol-
related deaths in the EU in 2016 [17]. This study was per-
formed in the frame of cooperation between the European
Medicines Agency and the EMCDDA to support its project
on ‘Misuse of tramadol within the context of poly-drug use—
an emerging concern?’
The study aimed to characterise trends in tramadol pre-
scribing in primary care in two large EU countries which have
not scheduled tramadol as a narcotic, during a 10-year period
between 1 January 2006 and 30 June 2016, including six-
monthly estimates of prevalence, and intended doses and du-
rations in tramadol prescriptions. A further aim was to esti-
mate the proportion of patients starting treatment with trama-
dol that continue treatment for 12 months or longer and may
be at increased risk of developing abuse or dependence. Long-
term opioid treatment has not been consistently defined in the
literature [18]. Our goal was to capture patients that continue
treatment beyond a minimum of 3–6 months typically re-
quired to fulfil the definition for chronic pain [19]. We
hypothesised that the risk of long-term treatment could be
influenced by age, gender, dose, the type of tramadol product
prescribed, indication for treatment and a history of abuse or
misuse, and that similar factors could also influence doses and
durations in individual prescriptions.
Methods
Data source
The study used French and German primary care electronic
health record data from IMS® Disease Analyzer (October
2016 release). Tramadol prescribing in patients 18 years or
older was studied in general practices that continuously pro-
vided data over a 10-year period from 1 January 2006 to 30
June 2016. Both databases contain a representative panel of
general practitioners (GPs) and cover around 2% and 3% of all
GP practices in France and Germany, respectively. The age
and gender distribution of adult patients included in the data-
bases is representative of the general population [20, 21]. The
databases contain information on diagnoses and prescriptions,
and data from Germany also contain information on lifestyle
factors. In both countries, patients are not required to register
with a GP to receive care. Therefore, denominators for prev-
alence calculations are based upon patients consulting at GP
practices within the specified time periods, i.e. active patients,
and not the entire population denominator.
Tramadol exposure
All products containing tramadol were included in the study.
The IMS Disease Analyzer databases in Germany and France
use EphMRA ATC codes for classification. All tramadol con-
taining products are classified as EphMRAATC code N02B0.
We considered the following categories or types of tramadol
products: tramadol in combination with paracetamol, imme-
diate release (IR) formulations of plain tramadol (all plain
tramadol formulations excluding slow release formulations)
and slow release (SR) formulations of plain tramadol.
Prescription records in IMS® Disease Analyzer contain
information about the prescribed product or substance, includ-
ing the strength and pack size where available, and informa-
tion about the amount prescribed. In France, information
about the daily dose, frequency of intake, prescribed quantity
(number of packs) and duration is extracted by IMS® from an
unstructured ‘physician dosage instruction text’. In Germany,
the prescribed quantity is provided directly by the physician.
Information about the daily dose is extracted by IMS® from a
free text field. Duration is then calculated by IMS® from the
daily dose and the prescribed quantity. We did not include
liquid formulations in calculations of intended doses and du-
rations due to limited information allowing dose or duration to
be reliably estimated. These formulations represented 2% of
tramadol prescriptions in adult patients in France and 27% in
Germany.
Intended daily doses and durations in individual prescrip-
tions were calculated, where possible. Multiple same day pre-
scriptions for a patient were considered together; total doses
were summed and the prescription with the longest duration
was selected as duration. Daily dose was calculated only if
information on dose was available in all prescriptions on the
same date. The mean dose and mean duration in all prescrip-
tions for the patient during the study period was calculated.
Prescriptions were then ranked by date of prescription, and the
first tramadol prescription during the study period was defined
as incident or prevalent exposure. Incident tramadol exposure
was defined as a prescription for tramadol in a patient with at
least 365 days of observation with no prescription within the
previous 365 days.
Individual prescriptions were combined in order to calcu-
late the total treatment duration following incident exposure.
Treatment was considered to belong to the same treatment
episode until there was a gap of more than 30 days between
calculated treatment dates. End of exposure was defined as the
date for the previous prescription, plus its duration. Tramadol
prescriptions with a gap of 366 days or more instead repre-
sented a new treatment episode and were considered as new
incident exposure. In order to reduce the risk of incorrect
classification of the exposure as short-term, we censored total
treatment durations of less than 366 days if the patient had no
further prescriptions for tramadol, considering the possibility
that the patient may have continued treatment in another prac-
tice, which could not be identified in the database. The mean
duration of prescriptions for the same treatment episode was
imputed if duration was missing and at least one of the
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prescriptions in that treatment episode had data to calculate the
duration. A sensitivity analysis was undertaken using only
patients with complete prescription duration data. Due to a
low percentage of incident prescriptions with data on duration
in Germany (23% of all prescriptions), a further sensitivity
analysis was performed imputing the median duration of all
available prescriptions in all patients according to the type of
tramadol product in case of missing data on duration among
all prescriptions for the same treatment episode.
To increase the validity of exposure data, daily doses
(France and Germany) and duration (France only) recorded
by IMS® were reviewed against data contained within physi-
cian free text fields of the prescription. Durations of single
prescriptions greater than 365 days were considered incorrect
and were excluded from the analysis (0.02% of prescriptions
in France and 0.0002% of prescriptions in Germany).
Indications for tramadol prescribing and diagnosis
of abuse and misuse
In order to investigate risk factors for long-term tramadol
use, clinical diagnoses were identified by screening ICD 10
diagnosis codes recorded on the same day as the incident
tramadol prescription, excluding ICD codes Z70.0 to
Z76.9 (i.e. persons encountering health services in other
circumstances). The most common ICD 10 codes compris-
ing 0.5% or more of all tramadol prescriptions were
reviewed by two clinical investigators, to categorise indi-
cations for tramadol.
Furthermore, ICD-10 codes suggestive of abuse and mis-
use [22–26] recorded up to the time of the incident tramadol
prescription were also identified and included the following:
F10.0-F10.9 Mental and behavioural disorders due to use of
alcohol; F11.0-F11.9 Mental and behavioural disorders due to
use of opioids; F12.0-F12.9 Mental and behavioural disorders
due to use of cannabinoids; F13.0-F13.9 Mental and behav-
ioural disorders due to use of sedatives or hypnotic; F14.0-
F14.9Mental and behavioural disorders due to use of cocaine;
F15.0-F15.9 Mental and behavioural disorders due to use of
other stimulants, including caffeine; F16.0-F16.9 Mental and
behavioural disorders due to use of hallucinogen; F18.0-F18.9
Mental and behavioural disorders due to use of volatile sol-
vents; F19.0-F19.9 Mental and behavioural disorders due to
use of multiple drug use and use of other psychoactive sub-
stances; Z50.2 Alcohol rehabilitation; Z50.3 Drug rehabilita-
tion; Z71.4 Alcohol use counselling and surveillance; Z71.5
Drug use counselling and surveillance; Z72.1 Alcohol use and
Z72.2 Drug use.
Analysis
The prevalence of tramadol prescribing was calculated using
six-monthly time periods, examining trends by gender, age
group (18–29, 30–39, 40–49, 50–59, 60–69, 70–79, 80–89
and 90–99 years) and type of tramadol product. The numera-
tor for these calculations included patients with a tramadol
prescription, and the denominator included all patients with
a consultation, respectively, during each time period. In a post-
hoc analysis, Joinpoint regression using the grid search meth-
od and permutation testing for model selection was used to
determine at what point statistically significant changes in
trend for prevalence of tramadol prescribing occurred [27].
Doses and durations in individual prescriptions were
analysed by incident or prevalent use at the start of the study,
and by gender, age group, type of tramadol product, total
number of tramadol prescriptions during the study period
(1–9, 10–49 and ≥ 50 prescriptions) and year at the start of
the study. Doses were also analysed by prescription rank until
fewer than 100 patients had received as many or more pre-
scriptions during the study period.
Long-term treatment was defined as a continuous treatment
episode of 366 days or longer. Risk factors for long-term treat-
ment vs. shorter treatment duration were investigated using
multivariable logistic regression and calculating adjusted odds
ratios (ORs) for long-term treatment for the following baseline
variables: gender, age group, type of tramadol product,
starting dose, clinical indication and a recorded history of
ICD codes suggestive of abuse or misuse.
Sensitivity analysis was performed, excluding from the ref-
erence group patients with evidence of continued tramadol use
for at least 181 days during the first 365 days after the incident
exposure, irrespective of whether gaps of 31 days between
prescriptions had occurred. Additional sensitivity analysis
was performed, excluding from the reference group patients
with episodes of long-term use after the initial short-term treat-
ment episode and prior to any subsequent incident exposure.
SAS Enterprise Guide version 6.1 was used for analysis of
long-term treatment
All analyses in the study were own analyses based on data
available in the IMS® Disease Analyzer databases.
Results
Overall trends in tramadol prescribing
Trends in prevalent prescribing of tramadol by gender in GP
practices in France and Germany are shown in Fig. 1. In both
France and Germany, prescribing was higher in females com-
pared with males. Prescribing increased with increasing age
(Supplementary material, Fig. A1). Compared to France, the
prevalence of tramadol prescribing in Germany fell during the
entire study period (Fig. 1). A significant change in trend
resulting in decreased prescribing was identified in France
but not in Germany (Supplementary material, Table A1).
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In France, the most commonly prescribed tramadol type was
tramadol in combination with paracetamol (59.7% of total,
Fig. 2), which showed a similar trend as the overall tramadol
prescribing, followed by plain tramadol SR formulations, then
plain tramadol IR formulations until 2014, when plain tramadol
IR formulations became more frequent than SR formulations.
The changes in trend during 2014 for plain tramadol IR and
SR formulations were both significant (Supplementary
material, Table A1). In Germany, the most commonly prescribed
type was plain tramadol SR formulations (56.1% of total, Fig. 2),
followed by plain tramadol IR formulations and tramadol in
combination with paracetamol. Significant decreases in trend
were observed for all three tramadol types, with an earlier change
for tramadol combinations that was later followed by significant
increase in trend (Supplementary material, Table A1).
Dose and duration
Daily dose was calculated in 77.4% (n = 244,006) and
duration in 90.8% (n = 286,292) of all tramadol
prescriptions in France (n = 471,839) compared to only
19.7% (n = 93,084) and 20.0% (n = 94,516) of all trama-
dol prescriptions (n = 315,433) in Germany. Initial and
mean doses and mean durations by incident or prevalent
use at study start, gender, age group, type of tramadol
and total number of tramadol prescriptions during the
study period are shown in Tables 1 and 2. For initial
and mean doses and mean durations by year at start,
please see Supplementary material (Table A2). In both
countries, doses and durations in tramadol prescriptions
were greater in prevalent compared to incident users
(Tables 1 and 2). The highest doses were prescribed to
males and those in the middle age groups. Dose and
duration was higher for plain tramadol SR formulations,
followed by plain tramadol IR formulations then trama-
dol in combination with paracetamol, whilst patients ini-
tiating treatment with more than one tramadol formula-
tion type had the highest doses and durations. In general,
mean daily doses increased with increasing number of repeat
prescriptions (Fig. 3). The findings were largely driven by non-
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Fig. 2 a–b Number of adult patients prescribed tramadol by type of tramadol product per 1000 active patients in France and Germany. a IMS® France
(left side). b IMS® Germany (right side)
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Fig. 1 a–bNumber of adult patients with a tramadol prescription and number of prescriptions for tramadol per 1000 active patients by gender in France
and Germany. a IMS® France (left side). b IMS® Germany (right side)
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incident users at the time of the first tramadol prescription during
the study period and plain tramadol SR formulations.
Indications for tramadol prescribing and long-term
treatment
Clinical indications were identified in 72.1% and 80.2% of
patients initiating tramadol in France and Germany, respec-
tively. The most frequent indication for tramadol prescribing
was ‘dorsopathy’, followed by ‘arthropathies’ and ‘injuries’
(Supplementary material, Table A3). The prevalence of long-
term use following tramadol initiation was 1.5% in France and
8.2% in Germany.
Risk factors for long-term treatment are shown in
Table 3. Long-term treatment was associated with increas-
ing age, a history of ICD codes suggestive of abuse or
misuse and treatment with plain tramadol SR formulations.
In Germany, a clinical indication of ‘pain not elsewhere
classified’, and in France other clinical indications than
those that had been classified in the study were associated
with long-term treatment. There was no strong evidence
that any of the other classified clinical indications were
associated with long-term treatment whilst a history of
‘dorsopathy’ was associated with a reduced risk of long-
term treatment. Results were similar for the pre-specified
sensitivity analyses.
Table 1 Initial dose (the initial dose was the first recorded tramadol
dose for the patient during the study period. The initial dose could be
calculated in 69,214 patients (76.1%)), mean dose and mean duration (the
mean dose and mean duration was calculated as the mean of all recorded
tramadol doses and durations for the patient during the study period. Dose
could be calculated in 73,597 patients (80.9%) and duration in 83,841
patients (92.1%)) of tramadol prescribing by incident use (for the purpose
of this table, only the first tramadol prescription during the study period
was classified as incident or not), gender, age group, type of tramadol
product and total number of tramadol prescriptions during the study
period (between 1 January 2006 and 30 June 2016) in France
France Initial dose in mg; mean
(95% CI)
Mean dose in mg; mean
(95% CI)
Mean duration in days; mean
(95% CI)
All patients (n = 90,987) 146.5 (146.0–147.0) 149.7 (149.2–150.2) 21.1 (20.9–21.2)
Incident or prevalent use at start
▪ Incident use (n = 64,711) 142.9 (142.4–143.5) 146.2 (145.7–146.8) 20.6 (20.4–20.7)
▪ Prevalent use (n = 26,276) 155.2 (154.2–156.3) 158.3 (157.2–159.3) 22.4 (22.1–22.7)
Gender
▪ Males (n = 41,626) 149.3 (148.5–150.1) 152.6 (151.8–153.3) 20.2 (20.0–20.4)
▪ Females (n = 49,361) 144.2 (143.5–144.9) 147.3 (146.7–148.0) 21.8 (21.6–22.0)
Age category at start
▪ Start age 18–29 years (n = 10,163) 141.3 (139.9–142.7) 143.7 (142.3–145.0) 15.6 (15.3–15.9)
▪ Start age 30–39 years (n = 14,341) 145.9 (144.6–147.2) 149.2 (147.9–150.4) 17.1 (16.8–17.4)
▪ Start age 40–49 years (n = 18,723) 149.6 (148.5–150.8) 153.2 (152.1–154.3) 18.7 (18.5–19.0)
▪ Start age 50–59 years (n = 18,848) 150.2 (149.0–151.4) 153.0 (151.9–154.2) 21.3 (21.0–21.6)
▪ Start age 60–69 years (n = 13,753) 147.3 (145.9–148.7) 151.4 (150.1–152.7) 24.3 (23.9–24.7)
▪ Start age 70–79 years (n = 9886) 144.3 (142.7–145.9) 147.1 (145.6–148.6) 27.2 (26.7–27.7)
▪ Start age 80–89 years (n = 4821) 136.9 (134.7–139.1) 140.2 (138.1–142.3) 29.8 (29.1–30.6)
▪ Start age 90–99 years (n = 444) 125.6 (118.9–132.3) 129.4 (122.4–136.4) 29.2 (26.7–31.6)
Type of formulation at start
▪ Tramadol in combination with paracetamol1
(n = 65,838)
128.6 (128.2–129.0) 133.9 (133.4–134.3) 19.3 (19.1–19.4)
▪ Immediate release plain tramadol2 (n = 10,573) 161.7 (160.0–163.4) 164.6 (163.1–166.2) 23.7 (23.2–24.2)
▪ Slow release plain tramadol3 (n = 13,752) 203.3 (201.5–205.0) 199.8 (198.2–201.4) 27.2 (26.9–27.6)
▪ More than one formulation type (n = 824) 314.7 (304.9–324.4) 267.2 (258.4–276.1) 32.7 (31.0–34.3)
Total number of prescriptions
▪ ≥ 50 prescriptions (n = 447) 194.5 (184.0–205.1) 223.0 (213.2–232.7) 27.5 (26.5–28.5)
▪ 10–49 prescriptions (n = 6056) 159.8 (157.4–162.2) 173.7 (171.6–175.9) 35.5 (34.9–36.1)
▪ 1–9 prescriptions (n = 84,484) 145.2 (144.7–145.7) 147.2 (146.7–147.7) 19.9 (19.8–20.1)
CI confidence interval. Own calculations, based on IMS® Disease Analyzer France
1Amount of tramadol per dose form, 37.5 mg
2Amount of tramadol per dose form, 50 and 100 mg
3Amount of tramadol per dose form, 50, 100, 150, 200 and 300 mg
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Discussion
Our study found that tramadol prescribing was more prev-
alent in females, and increased with increasing age whilst
higher doses were prescribed more often to males and
people in their middle ages. The prevalence of tramadol
prescribing appeared to have fallen in Germany compared
to France. Results from Germany are in keeping with a
previous study using German insurance data that showed
a decrease in the prevalence of prescribing of plain tram-
adol IR formulations by 39.6% and an increase in pre-
scribing of plain tramadol SR formulations of 102.7%
between 2001 and 2010 [28].
Mean daily doses of tramadol appeared to steadily increase
with increasing number of prescriptions received by patients
during the study period. Tolerance and physical dependence
are expected effects of opioids [29], resulting in a need to
increase the dose up to ten times the original dose to maintain
the same analgesic effect. In a review of spontaneously report-
ed cases with tramadol dependence, prescribed doses had
ranged up to 800 mg per day with ingested doses up to
4000 mg per day [30], and in a published case report, a young
woman with a history of depression had increased the dose of
tramadol, which improved mood and produced euphoria [31].
Development of tolerance is one of several criteria for opioid
use disorder according to DSM 5 [32], although most patients
Table 2 Initial dose (the initial dose was the first recorded tramadol
dose for the patient during the study period. The initial dose could be
calculated in 17,418 patients (17.8%), mean dose and mean duration (the
mean dose and mean duration was calculated as the mean of all recorded
tramadol doses and durations for the patient during the study period. Dose
could be calculated in 22,534 patients (23.0%) and duration in 22,724
patients (23.2%)) of tramadol prescribing by incident use (for the purpose
of this table, only the first tramadol prescription during the study period
was classified as incident or not), gender, age group, type of tramadol
product and total number of tramadol prescriptions during the study
period (between 1 January 2006 and 30 June 2016) in Germany
Germany Initial dose in mg; mean
(95% CI)
Mean dose in mg; mean
(95% CI)
Mean duration in days;
mean (95% CI)
All patients (n = 97,809) 147.1 (146.0–148.3) 156.3 (155.2–157.4) 31.9 (31.6–32.2)
Incident or prevalent use at start
▪ Incident use (n = 72,638) 142.8 (141.6–144.0) 150.5 (149.4–151.6) 30.4 (30.1–30.8)
▪ Prevalent use (n = 25,171) 161.3 (158.6–164.1) 178.6 (171.1–176.1) 36.3 (35.6–36.9)
Gender
▪ Males (n = 41,427) 152.6 (150.8–154.4) 161.2 (159.6–162.9) 30.8 (30.3–31.2)
▪ Females (n = 56,368) 142.8 (141.3–144.2) 152.6 (151.2–153.9) 32.8 (32.4–33.2)
Age category
▪ Start age 18–29 years (n = 4013) 139.1 (133.8–144.4) 145.3 (139.4–151.2) 21.6 (20.5–22.8)
▪ Start age 30–39 years (n = 7075) 145.6 (141.2–150.1) 154.5 (149.9–159.1) 24.3 (23.3–25.3)
▪ Start age 40–49 years (n = 13,405) 148.5 (145.3–151.7) 160.6 (157.5–163.7) 27.2 (26.4–27.9)
▪ Start age 50–59 years (n = 17,125) 147.9 (145.2–150.6) 160.1 (157.4–162.8) 30.2 (29.5–30.9)
▪ Start age 60–69 years (n = 17,228) 151.2 (148.4–154.1) 160.9 (158.3–163.5) 33.6 (32.8–34.4)
▪ Start age 70–79 years (n = 22,462) 147.8 (145.5–150.1) 155.9 (153.8–157.9) 34.8 (34.2–35.5)
▪ Start age 80–89 years (n = 14,923) 143.5 (140.8–146.2) 149.0 (146.7–151.4) 35.9 (35.1–36.7)
▪ Start age 90–99 years (n = 1577) 136.6 (129.1–144.1) 140.8 (133.7–147.9) 37.3 (34.8–39.7)
Type of formulation at first use
▪ Tramadol in combination with paracetamol1 (n = 4922) 90.2 (87.9–92.6) 101.5 (98.5–104.4) 21.7 (20.8–22.7)
▪ Immediate release plain tramadol2 (n = 43,235) 94.3 (92.8–95.8) 124.6 (122.7–126.5) 28.2 (27.7–28.7)
▪ Slow release plain tramadol3 (n = 49,061) 164.2 (162.9–165.5) 170.8 (169.5–172.0) 33.9 (33.6–34.3)
▪ More than one formulation type (n = 591) 228.8 (172.1–285.6) 221.6 (187.5–255.7) 32.4 (29.2–35.6)
Total number of prescriptions
▪ ≥ 50 prescriptions (n = 1450) 193.6 (177.1–210.0) 226.0 (216.1–235.9) 45.1 (43.5–46.8)
▪ 10–49 prescriptions (n = 8472) 164.9 (160.2–169.7) 182.5 (179.2–185.8) 47.9 (47.1–48.8)
▪ 1–9 prescriptions (n = 87,887) 144.9 (143.7–146.0) 149.5 (148.4–150.5) 28.7 (28.4–29.0)
CI confidence interval. Own calculations, based on IMS® Disease Analyzer Germany
1Amount of tramadol per dose form, 37.5 and 75 mg
2Amount of tramadol per dose form, 50 and 100 mg
3Amount of tramadol per dose form, 50, 100, 150, 200, 300 and 400 mg
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with tolerance do not develop opioid addiction [29]. A wors-
ening of the underlying chronic pain condition may, however,
also explain some of the observed dose increases.
The prevalence of long-term prescribing following
tramadol initiation was 1.5% and 8.2% in France and
Germany, respectively, although in Germany, the result
was based on a smaller proportion of incident use where
duration could be calculated (23% vs. 92%). The propor-
tion of patients with long-term treatment in Germany was
similar to the results from a previous study of opioids using
data from IMS® Disease Analyzer in Germany [33]. Risk
factors for long-term treatment appeared to include in-
creasing age, a history of abuse or misuse and treatment
with plain tramadol SR formulations. In Germany, a clini-
cal indication of unclassified pain was also associated with
long-term treatment, whereas in France, a clinical indica-
tion other than those that had been classified in the study
appeared to be associated with long-term treatment. One
potential reason for the lower prevalence of long-term use
in France may be the predominant prescribing of tramadol
in combination with paracetamol in France in contrast to
Germany, where plain tramadol SR formulations was most
commonly prescribed, as tramadol in combination with
paracetamol was associated with a significantly lower like-
lihood of long-term use compared to plain tramadol SR
formulations. However, initiating treatment with plain
tramadol SR formulations may be due to anticipated
long-lasting conditions, thus increasing the likelihood of
longer-term treatment if well tolerated. This bias may not
have been sufficiently controlled for by including the most
common indications for tramadol treatment in the analysis.
An association between long-term treatment and a diagno-
sis of unclassified pain in Germany is consistent with findings
from a previous study, which suggested that unexplained pain
tended to be persistent [34]. Complex regional pain syndrome,
fibromyalgia and visceral pain problems may underlie a
diagnosis of unclassified pain [35]. A diagnosis of unclassi-
fied pain has been shown to be associated with high rates of
outpatient and emergency department visits [36].
In light of reports of tramadol abuse occurring when
used for periods longer than weeks to months [7, 8], par-
ticularly in case of high doses, this study was conducted
to examine trends in tramadol prescribing in France and
Germany and identify risk factors for long-term use. This
is important because drug-related opioid deaths have been
shown to increase with increasing number of problem
opioid users [37]. We considered that it is relevant to
study patients that initiate treatment with tramadol and
continue for more than 1 year as well as patients that have
a high number of prescriptions for tramadol in order to
gain more insight into potential problem opioid use of
tramadol. The factors that we identified as risk factors
for long-term use, i.e. increasing age, plain tramadol SR
formulations and a history of abuse or misuse have previ-
ously been identified as factors that increase the risk of
opioid overdose [38], and a history of abuse or misuse has
been previously identified as a factor that increases the
risk of opioid addiction [38]. Results are also in keeping
with an increase in chronic pain with increasing age [39].
We did not, as we had expected, identify an association
between the tramadol dose and the risk of long-term use
independent of the tramadol formulation. However, as the
dose differed between tramadol types, and was higher for
plain tramadol SR formulations, which was associated
with a higher risk of long-term use, compared to the other
two tramadol formulations, it is possible that the identi-
fied increased risk of long-term use with plain tramadol
SR formulations was at least in part due to a higher dose
for this formulation. It is also possible that the increased
risk of opioid overdose with the use of high opioid doses
[38] relates more to dose increases during treatment than
to the starting dose itself.
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Fig. 3 a–bMean difference (95% confidence interval) in dose compared
to initial dose of tramadol in milligramme in consecutive prescriptions of
tramadol between 2006 and 2016 in France and Germany. a IMS®
France (left side). b IMS® Germany (right side). LCL lower confidence
limit, UCL upper confidence limit
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Table 3 Risk factors for long-term (> 365 days) tramadol use among incident tramadol users
France (N = 37,078)
OR (95% CI)1
Germany (N = 9219)
OR (95% CI)1
Gender
Male 1.0 (ref.) 1.0 (ref.)
Female 1.01 (0.85–1.20) 1.10 (0.94–1.30)
Age group2
Age 18–29 years 1.0 (ref.) 1.0 (ref.)
Age 30–39 years 1.12 (0.43–2.88) 0.74 (0.27–1.98)
Age 40–49 years 1.79 (0.76–4.22) 1.48 (0.63–3.50)
Age 50–59 years 3.90 (1.71–8.89) 1.44 (0.62–3.35)
Age 60–69 years 5.71 (2.51–12.98) 1.87 (0.81–4.33)
Age 70–79 years 8.44 (3.71–19.18) 1.85 (0.81–4.26)
Age 80–89 years 15.49 (6.78–35.37) 3.11 (1.35–7.15)
Age 90–99 years 24.86 (9.13–67.71) 3.87 (1.50–10.00)
Type of tramadol product2
Plain SR 1.0 (ref.) 1.0 (ref.)
Plain IR 0.71 (0.54–0.94) 0.50 (0.41–0.60)
Comb 0.50 (0.41–0.62) 0.49 (0.33–0.73)
More than one tramadol type 1.83 (1.07–3.12) 1.23 (0.55–2.77)
Tramadol dose2, 3
Dose 0–< 150 mg 1.0 (ref.) 1.0 (ref.)
Dose 150–< 300 mg 0.88 (0.73–1.06) 0.77 (0.64–0.94)
Dose ≥ 300 mg 1.13 (0.82–1.56) 1.02 (0.70–1.50)
Indication (ICD codes)2
Dorsopathy (M40–M54) 0.44 (0.34–0.57) 0.73 (0.61–0.87)
Arthropathies (M00-M25) 0.75 (0.55–1.02) 1.17 (0.95–1.45)
Soft tissue disorders (M60-M79) 0.50 (0.32–0.78) 0.86 (0.59–1.24)
Injuries (S00-T14) 0.53 (0.29–0.98) 0.79 (0.56–1.11)
Pain not elsewhere classified (R52) 1.56 (0.84–2.89) 1.58 (1.26–1.99)
Nerve, nerve root and plexus disorders, polyneuropathy, and
diabetic nerve complications (G50-G59, E10.4, E11.4, E12.4,
E13.4, E14.4, G60-G63)
0.77 (0.43–1.38) 1.31 (0.86–1.98)
Osteopathies, chondropathies and other disorders of the musculoskeletal
system and connective tissue (M80-M99)
0.97 (0.51–1.85) 0.86 (0.60–1.23)
Herpes zoster (B02) 0.00 (0.00–999.99) 0.34 (0.14–0.84)
Pain in throat and chest, periapical abscess, and acute pharyngitis and tonsillitis
(R07, K046, K047, J02-J03)
0.45 (0.15–1.43) 0.31 (0.04–2.31)
Abdominal pain, diseases of oesophagus, stomach and duodenum, unspecified
gastritis and colitis, diverticular disease, irritable bowel syndrome, and
cholelithiasis (R10, K20-K30, A09.9, K57-K58, K80)
1.34 (0.76–2.36) 1.10 (0.82–1.46)
Headache, migraine (R51, G43-G44) 1.75 (0.85–3.59) 0.79 (0.32–1.96)
Other than the above 1.28 (1.04–1.58) 1.21 (0.94–1.56)
Any ICD code for abuse or misuse4 1.96 (1.26–3.04) 1.76 (1.32–2.34)
CI confidence interval,OR odds ratio. Own analyses, based on IMS®DiseaseAnalyzer (France andGermany). Significant p values (<0.05) are shown in
italics
1 Adjusted odds ratios. Factors included in the model: Gender, age group at start of incident treatment, type of tramadol product at start of incident
treatment, dose category at start of incident treatment, existence of any code or abuse or misuse recorded at start of treatment or earlier, and indication at
start of incident treatment
2 At start of incident treatment
3 The mean incident dose was imputed in case of missing information on dose
4 ICD codes F10-F16, F18-F19, Z50.2, Z50.3, Z72.2 and Z86 recorded at start of treatment or earlier (2.6%, n = 960 in France; 5.6%, n = 516 in
Germany)
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Strengths and limitations
This study uses large electronic health care databases with
a high level of granularity of data on prescribing to exam-
ine patterns of tramadol prescribing and risk factors for
long-term use in two major European countries.
However, our study has several potential weaknesses.
Not all of our results were consistent between data
sources, which may relate to differences in health care
practices, quality of data recording, power for analysis
and ability to accurately follow up patients over time.
The latter may potentially lead to an underestimation in
the prevalence of long-term use, although we tried to min-
imise this risk by censoring total treatment durations of
less than 366 days if the patient had no further prescrip-
tions for tramadol. For some patients, tramadol prescrip-
tion data was incompletely recorded; however, sensitivity
analyses were conducted using different definitions with
similar results. A comparatively high proportion of pre-
scriptions in Germany, 27% vs. 2% in France, concerned
liquid formulations that were not included in the calcula-
tion of duration. Our results may not, therefore, be repre-
sentative for patients treated with liquid formulations of
tramadol. Overall, duration could only be calculated in
23% of all incident use in Germany vs. 92% in France,
making results from Germany more susceptible to poten-
tial biases. A further limitation of the study includes the
possibility that diagnoses may be incompletely recorded.
Hence, the associations between the indication for treat-
ment or a history of ICD codes suggestive of abuse or
misuse and long-term tramadol treatment may be
underestimated. Moreover, since the study is based on
prescriptions, it is unknown to what extent the patients
have actually visited the pharmacy to dispense the treat-
ment. Lastly, it is uncertain how our results are generaliz-
able to other countries in Europe and beyond.
Conclusion
Tramadol abuse may occur [7, 8] if used for long periods at
high doses. Male patients, middle aged patients and those
receiving large number of prescriptions have the highest
doses, whilst increasing age, a history of conditions associated
with abuse or misuse and initiation of treatment with plain
tramadol SR formulations were identified as risk factors for
long-term use suggesting these types of patients could be
targeted for medication review and may be at increased risk
of tramadol abuse. In Germany, a diagnosis of unclassified
pain was also associated with long-term use. Further evidence
is required to determine whether the tramadol SR formulation
itself is a risk factor for long-term use independent of the dose
or indication for treatment.
Acknowledgments The authors would like to thank EMCDDA for shar-
ing their emerging concern about misuse and fatal intoxications of tram-
adol in the context of poly-drug use.
Compliance with ethical standards
Conflict of interest The authors are employees of the European
Medicines Agency and have no conflicts of interest in relation to this
article.
Disclaimer The views expressed in this article are the personal views of
the authors and may not be understood or quoted as being made on behalf
of or reflecting the position of the European Medicines Agency or one of
its committees or working parties.
OpenAccessThis article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduc-
tion in any medium, provided you give appropriate credit to the original au-
thor(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made.
Publisher’s Note Springer Nature remains neutral with regard to juris-
dictional claims in published maps and institutional affiliations.
References
1. Lassen D, Damkier P, Brosen K (2015) The pharmacogenetics of
tramadol. Clin Pharmacokinet 54(8):825–836
2. Dependence ECoD (2014) Tramadol update review report. Geneva,
Switzerland
3. Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F
(2007) Concentrations of tramadol and O-desmethyltramadol enan-
tiomers in different CYP2D6 genotypes. Clin Pharmacol Ther
82(1):41–47
4. Stamer UM, Stuber F (2007) Codeine and tramadol analgesic effi-
cacy and respiratory effects are influenced by CYP2D6 genotype.
Anaesthesia 62(12):1294–1295 author reply 5-6
5. Radbruch L, Glaeske G, Grond S, Munchberg F, Scherbaum N,
Storz E et al (2013) Topical review on the abuse and misuse poten-
tial of tramadol and tilidine in Germany. Subst Abus 34(3):313–320
6. EMCDDA (2017) Legal topic overviews: classification of con-
trolled drugs. EMCDDA, Lisbon Available from: http://www.
emcdda.europa.eu/html.cfm/index146601EN.html#national.
Accessed 25 Sept 2017
7. Casati A, Sedefov R, Pfeiffer-Gerschel T (2012) Misuse of medi-
cines in the European Union: a systematic review of the literature.
Eur Addict Res 18(5):228–245
8. Garcia-Orjuela MG, Alarcon-Franco L, Sanchez-Fernandez JC,
Agudelo Y, Zuluaga AF (2016) Dependence to legally prescribed
opioid analgesics in a university hospital in Medellin-Colombia: an
observational study. BMC Pharmacol Toxicol 17(1):42
9. Tjaderborn M, Jonsson AK, Hagg S, Ahlner J (2007) Fatal unin-
tentional intoxications with tramadol during 1995-2005. Forensic
Sci Int 173(2–3):107–111
10. Giraudon I, Lowitz K, Dargan PI, Wood DM, Dart RC (2013)
Prescription opioid abuse in the UK. Br J Clin Pharmacol 76(5):
823–824
11. Leifman H (2016) Drug-related deaths in Sweden - estimations of
trends, effects of changes in recording practice and studies of drug
patterns. Sweden, Stockholm
12. Green TC, Grau LE, Carver HW, Kinzly M, Heimer R (2011)
Epidemiologic trends and geographic patterns of fatal opioid
Eur J Clin Pharmacol
intoxications in Connecticut, USA: 1997-2007. Drug Alcohol
Depend 115(3):221–228
13. Lapatto-Reiniluoto O, Vuori E, Hoppu K, Ojanpera I (2013) Fatal
poisonings in Finland during the years 2004-2009. Hum Exp
Toxicol 32(6):600–605
14. Hakkinen M, Launiainen T, Vuori E, Ojanpera I (2012)
Comparison of fatal poisonings by prescription opioids. Forensic
Sci Int 222(1–3):327–331
15. Martins SS, Sampson L, CerdaM, Galea S (2015)Worldwide prev-
alence and trends in unintentional drug overdose: a systematic re-
view of the literature. Am J Public Health 105(11):e29–e49
16. Martins SS, Sampson L, CerdaM, Galea S (2015)Worldwide prev-
alence and trends in unintentional drug overdose: a systematic re-
view of the literature. Am J Public Health 105(11):2373
17. Giraudon I, Mathis F, Palczak K. Tramadol-related deaths 2016
survey overview Lisbon, Portugal 2016. Available from: http://
emcdda.europa.eu/system/files/attachments/3236/Isabelle%
20Giraudon-06.%20Tramadol%20related%20deaths_updated_
2609 2016_final-1.pdf_en
18. Darnall BD, Stacey BR, Chou R (2012) Medical and psychological
risks and consequences of long-term opioid therapy in women. Pain
Med (Malden, Mass) 13(9):1181–1211
19. McCarberg B (2007) Tramadol extended-release in the manage-
ment of chronic pain. Ther Clin Risk Manag 3(3):401–410
20. Becher H, Kostev K, Schroder-Bernhardi D (2009) Validity and
representativeness of the Bdisease analyzer^ patient database for
use in pharmacoepidemiological and pharmacoeconomic studies.
Int J Clin Pharmacol Ther 47(10):617–626
21. IQVIA/IMS Health, 30 August 2016, unpublished
22. World Health Organisation. F10-F19. Mental and behavioural disor-
ders due to psychoactive substance use. Available from: http://www.
who.int/substance_abuse/terminology/ICD10ClinicalDiagnosis.pdf
23. Fone D, Morgan J, Fry R et al (2016) Study 2: hospital admissions.
Change in alcohol outlet density and alcohol-related harm to pop-
ulation health (CHALICE): a comprehensive record-linked data-
base study in Wales Southampton, United Kingdom: NIHR
Journals Library
24. Committee GBPHoCH, Barron K (2006) Public Expenditure on
Health and Personal Social Services 2006: Memorandum
Received from the Department of Health Containing Replies to a
Written Questionnaire from the Committee; Written Evidence:
Stationery Office
25. Sambell C, Quan H, Johansen H (2006) Health Studies Using
Administrative Hospital Data. In: Proceedings of Statistics
Canada Symposium 2006 Methodological Issues in Measuring
Population Health [Internet]. Canada: Statistics Canada. Available
from: https://www.researchgate.net/publication/237520244_
Health_Studies_Using_Administrative_Hospital_Data/citations
26. McKenzie K, Harrison JE, McClure RJ (2010) Identification of
alcohol involvement in injury-related hospitalisations using routine
data compared to medical record review. Aust N Z J Public Health
34(2):146–152
27. Joinpoint Trend Analysis Software. Available from: https://
surveillance.cancer.gov/joinpoint/
28. Schubert I, Ihle P, Sabatowski R (2013) Increase in opiate prescrip-
tion in Germany between 2000 and 2010: a study based on insur-
ance data. Dtsch Arztebl Int 110(4):45–51
29. Morgan MM, Christie MJ (2011). Analysis of opioid efficacy, tol-
erance, addiction and dependence from cell culture to human.
British journal of pharmacology 164(4):1322–34
30. Tjaderborn M, Jonsson AK, Ahlner J, Hagg S(2009). Tramadol
dependence: a survey of spontaneously reported cases in Sweden.
Pharmacoepidemiol Drug Saf.;18(12):1192–8
31. Ferrari A, Tiraferri I, Palazzoli F, Licata M (2014). Tramadol abuse
in a binge pattern in a young depressed woman. Eur Addict
Res.;20(2):82–6
32. American Psychiatric Association (2013). Substance Use
Disorders. 5th ed. Washington, DC
33. Chevalier P, Smulders M, Chavoshi S, Sostek M, LoCasale R
(2014) A description of clinical characteristics and treatment pat-
terns observed within prescribed opioid users in Germany and the
UK. Pain Manag 4(4):267–276
34. Klaus K, Rief W, Brahler E, Martin A, Glaesmer H, Mewes R
(2013) The distinction between Bmedically unexplained^ and
Bmedically explained^ in the context of somatoform disorders. Int
J Behav Med 20(2):161–171
35. Jensen MP (2011) Hypnosis for chronic pain management: thera-
pist guide. Oxford University Press, Oxford
36. Romanelli RJ, Shah SN, Ikeda L, Lynch B, Craig TL, Cappelleri JC
et al (2017) Patient characteristics and healthcare utilization of a
chronic pain population within an integrated healthcare system.
Am J Manag Care 23(2):e50–ee6
37. Millar T, McAuley A. (2017) EMCDDA assessment of drug-
induced death data and contextual information in selected coun-
tries. Lisbon, Portugal. CT.15.IBS.0137.1.0
38. Volkow ND, McLellan AT (2016) Opioid abuse in chronic pain—
misconceptions and mitigation strategies. N Engl J Med 374(13):
1253–1263
39. Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT (2016)
Prevalence of chronic pain in the UK: a systematic review and
meta-analysis of population studies. BMJ Open 6(6):e010364
Eur J Clin Pharmacol
